-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prevention Atogepant is an oral small molecule CGRP receptor antagonist.
In this phase III, double-blind study, adult patients with migraine attacks 4-14 days per month participated and were randomized to receive Atogepant treatment or placebo once a day for 12 weeks.
873 patients participated in the study, including 214 in the 10mg Atogepant treatment group
After 12 days of treatment, the average monthly migraine attack days in the 10, 30, and 60 mg Atogepant treatment group and the placebo group changed from baseline to -3.
Studies believe that oral small molecule CGRP inhibitor Atogepant can effectively reduce the number of days of migraine attacks.
Oral small molecule CGRP inhibitor Atogepant can effectively reduce the number of migraine attacks.
Original source:
Jessica Ailani et al.
Atogepant for the Preventive Treatment of Migraine.
Leave a message here